NCH Appoints Dr. Patrick Smith as President of the Board of Directors of HSS at NCH Kapnick Ambulatory Surgical Center
EINPresswire.com / -- Naples Comprehensive Health (NCH) is pleased to announce the appointment of Patrick A. Smith, MD, as the new President of the Board of Directors of HSS at NCH Kapnick Ambulatory Surgical Center. Dr. Smith brings over three decades of experience in orthopedic surgery and sports medicine to this leadership role.
A Michigan native, Dr. Smith graduated with honors from the University of Michigan, where he also earned his medical degree. He completed both his surgical internship and orthopedic residency at the University of Michigan Medical Center. Following his residency, Dr. Smith pursued a one-year sports medicine fellowship under the mentorship of Jack C. Hughston, MD, at the Hughston Clinic in Columbus, Georgia. Dr. Smith is board certified by the American Board of Orthopedic Surgery and holds a subspecialty certification in Sports Medicine.
In 1986, Dr. Smith joined the Columbia Orthopedic Group in Columbia, Missouri, specializing in arthroscopic surgery and sports medicine. He served as Head Team Physician for the University of Missouri for 30 years and was instrumental in the care of athletes at the college. In recognition of his contributions, the training center at the University of Missouri football field was renamed the Patrick A. Smith Sports Medicine Center in his honor.
Throughout his career, Dr. Smith has been extensively involved in orthopedic research, publishing in numerous peer-reviewed journals. He conducted the first FDA-sanctioned study on the use of platelet-rich plasma to treat knee osteoarthritis and has been a pioneer in the use of internal bracing for anterior cruciate ligament (ACL) repair and reconstruction. Currently, he is engaged in clinical studies focusing on essential factors for rotator cuff healing.
'Dr. Smith's expertise, research, and deep commitment to patient care make him an invaluable addition to HSS at NCH,' said Paul Hiltz, President and CEO of NCH. 'His leadership will further our mission to provide world-class orthopedic care to our community, elevating the level of treatment available in Southwest Florida.'
'I am honored to join HSS at NCH and be part of a team dedicated to delivering world-class orthopedic care,' said Dr. Smith. 'Throughout my career, my passion has been advancing innovative treatments that improve patient outcomes, and I look forward to bringing that same commitment to Naples.'
Dr. Smith's passion for patient care and his openness to innovative procedures and technologies have been hallmarks of his career. His leadership is expected to further enhance the quality of orthopedic care at HSS at NCH.
About NCH
NCH (Naples Comprehensive Health) is an Advanced Community Healthcare System™ serving Southwest Florida with premier routine, critical, and specialty care. NCH, a locally governed non-profit, is recognized as one of Healthgrades America's Top 50 Hospitals which puts it in the top 1% in the nation for clinical excellence, in addition to being named a Top 50 Hospital for Surgical Care. The system is more than just two hospitals (referred to as the NCH Baker Hospital and NCH North Hospital) with a total of 713 beds - NCH is an alliance of over 750 physicians and medical facilities in dozens of locations throughout Southwest Florida and is the region's only Joint Commission accredited Comprehensive Stroke Center. NCH cardiac care is ranked top-3 in the state by Healthgrades. NCH collaborates with the Hospital for Special Surgery for orthopedics, Nicklaus Children's Hospital for pediatrics, and ProScan Imaging for radiology services, ensuring top-tier medical care is available in Southwest Florida. With the largest provider network, urgent/immediate care centers, diagnostic facilities, and two hospitals, NCH is always advancing the quality of care near you. For more information, visit www.NCHmd.org.
About HSS
HSS is the world's leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the 15th consecutive year), No. 3 in rheumatology by U.S. News & World Report (2024-2025), and the best pediatric orthopedic hospital in NY, NJ and CT by U.S. News & World Report 'Best Children's Hospitals' list (2023-2024). In a survey of medical professionals in more than 20 countries by Newsweek, HSS is ranked world #1 in orthopedics for a fourth consecutive year (2025). Founded in 1863, the Hospital has the lowest readmission rates in the nation for orthopedics,
Amanda Lucey
NCH
+1 239-460-7318
Legal Disclaimer:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals Group Company Limited, in a bid to expand its clinical-stage obesity portfolio. The licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist. Regeneron will acquire exclusive clinical development and commercial rights for HS-20094, a dual GLP-1/GIP receptor agonist, outside the Chinese Mainland, Hong Kong and Macau. Per the terms of the agreement, Regeneron will make an upfront payment of $80 million to Hansoh, with potential additional payments of up to $1.93 billion for achievement of development, regulatory and sales milestones. Any royalties on global net sales in the future (outside the designated territories) would be in the low double digits. HS-20094 has been evaluated in over 1,000 patients and administered as a weekly subcutaneous injection. The candidate has demonstrated promising efficacy and safety clinical data, suggesting a potentially similar profile to the only FDA-approved GLP-1/GIP receptor agonist. The candidate is currently being evaluated in a phase III study in obesity in China, and a phase IIb study in diabetes is ongoing. The in-licensing agreement for an obesity candidate will expand REGN's obesity pipeline, which includes trevogrumab. Regeneron recently announced positive interim results from the ongoing phase II COURAGE study investigating novel combinations of semaglutide (GLP-1 receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin) with or without garetosmab (anti-activin A) for the treatment of obesity. COURAGE was designed to investigate the quality of weight loss in patients with obesity. Results showed that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass, and further demonstrated that combining semaglutide with trevogrumab with or without garetosmab helped preserve lean mass while increasing loss of fat mass. Garetosmab is being evaluated for the treatment of fibrodysplasia ossificans progressive. The successful development of any obesity treatment will be a great boost for the company. We note that REGN has had a rough time so far this year. The stock got hammered last week after REGN and partner Sanofi SNY reported results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive pulmonary disease (COPD). While the AERIFY-1 study met the primary endpoint, AERIFY-2 did not meet the same. REGN and SNY are currently reviewing the data and plan to discuss the next steps with regulatory authorities. Year to date, REGN's shares have lost 31.7% compared with the industry's 3.2% decline. Image Source: Zacks Investment Research Regeneron's performance in the first quarter was dismal. The plunge in Eylea sales adversely impacted the top line. Eylea sales have been under pressure for some time now due to competition from Roche's Vabysmo. Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote Regeneron has a tough road ahead, as it will take a long time for Eylea HD to contribute significantly to the top line. Apart from Eylea, profits from the sales of asthma drug Dupixent are a primary growth driver for REGN. Regeneron has a collaboration agreement with Sanofi for Dupixent. While the obesity market is lucrative, REGN is a pretty late entrant here. The market is dominated by bigwigs like Novo Nordisk NVO and Eli Lilly LLY. The stupendous success of Novo Nordisk's obesity drug, Wegovy (semaglutide) and Eli Lilly's Zepbound has prompted many companies to join the bandwagon. Buoyed by this success, both Lilly and NVO have taken significant strides in developing their obesity portfolios further. Given the significant market potential of obesity, other players are also striving to grab a chunk of this pie. Regeneron currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Sanofi (SNY) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
New York Post
an hour ago
- New York Post
Michelle Beadle doubles down on Stephen A. Smith digs as radio feud intensifies
Michelle Beadle had plenty more to say after Wednesday's news that her former ESPN colleague, Stephen A. Smith, will replace her time slot on Mad Dog Sports Radio with his new Sirius XM show launching this September. Beadle, who went off about it Wednesday on her and Cody Decker's show, 'Beadle and Decker,' doubled down on her comments in an interview with Front Office Sports, acknowledging 'there's no love lost' between her and Smith. 'It's a reminder: We're just all pieces of s–t to someone. If you forgot, there it is,' Beadle said in an interview published Wednesday evening, adding she was 'blindsided' by the news when she found out. Advertisement 4 Michelle Beadle at 'Beadle & Decker' at the SiriusXM Studios in New York City. Getty Images ''The Hollywood Reporter' comes out — and there's his face. I was like, 'I should have known.' That was just kind of gross. I don't care that we're being replaced or what have you. It happens all the time. But a little respect would have been nice. Good Lord. I was totally blindsided. Just really embarrassed, to be honest.' Beadle, who left ESPN in 2019, explained that she's been at odds with the 'First Take' host for years — dating back to 2014, when she called out Smith on social media for controversial comments he made on domestic violence in the wake of ex-NFL player Ray Rice's violent assault on his now-wife. Advertisement 'I don't respect him,' Beadle said of Smith. 'I don't respect his work. He doesn't like me. This goes back to the Ray Rice stuff. He made some really piggish comments on the air. I responded; he got suspended for like two weeks. I think that was sort of the beginning of the end for anything. 'I just don't respect him. I think he gets things wrong all the time. I'm not talking about opinions; those can never be wrong. But factually, when you spread yourself so thin, it's hard to be right. Not a fan.' Smith, who made comments suggesting Rice's wife may have provoked the domestic violence attack, apologized and was suspended for one week by ESPN. 4 Stephen A. Smith speaks before the Game 2 of the 2025 Western Conference finals. NBAE via Getty Images Advertisement Beadle told FOS that her contract with SiriusXM runs through August, but she expects to finalize a buyout before then. 'It was sort of therapeutic … I thought we did a pretty cool show for two years,' she said. Smith's new SiriusXM show will debut Sept. 2, taking over 'Beadle and Decker,' which airs every weekday from 12-3 p.m. ET on the Mad Dog Sports Radio channel. 4 Michelle Beadle and Cody Decker speak on SiriusXM at Super Bowl LVIII on February 7, 2024 in Las Vegas, Nevada. Getty Images for SiriusXM Advertisement During Wednesday's show, Beadle was not happy about the news and explained how she and Decker found out that Smith's show would take over their time slot a few hours before it became public. Smith, who will offer his takes on the biggest sports headlines, announced his multi-year agreement with SiriusXM during an appearance on 'The Howard Stern Show' on Wednesday, and 'The Hollywood Reporter' followed with additional details. As a part of the deal, Smith will launch a second show, described as a 'weekly current events, pop culture and social commentary-focused show,' in September. 4 Stephen A. Smith and Chris 'Mad Dog' Russo speak on SiriusXM at Super Bowl LVIII on February 7, 2024 in Las Vegas, Nevada. Getty Images for SiriusXM Although Beadle said she won't rant any further, she won't shy away from the topic of Smith. 'We'll show up. We'll have a hockey game to react to — and a basketball game to preview,' she told FOS. 'I can't help the callers. I'll be honest with you: they're crazy. So whatever happens, happens. But we won't entice them to do it, I guess.' Before FOS published Beadle's interview, Smith responded to comments she made on her Wednesday show about being 'blindsided' by the news. Advertisement 'I want to state for the record just so everyone knows what kind of man I am and what kind of teammate I am. I had no idea that folks did not know,' Smith said on SiriusXM's VSiN Live program with Patrick Meagher and Dustin Swedelson. 'I was told by SiriusXM to wait until this morning on 'The Howard Stern Show to make the announcement.' Whatever communication they had with anybody who's there, where they're staying, where they're being moved to. Who's staying, who's going or whatever. It's none of my business.' Smith added he 'would never in a million years be unprofessional and inconsiderate of a contemporary or a colleague.' Beadle, who previously hosted ESPN's 'NBA Countdown,' is the host of 'Run It Back,' an NBA-focused talk show on FanDuel TV with former players Chandler Parsons and Lou Williams.
The Hill
an hour ago
- The Hill
Blue states call on FDA to expand abortion pill access
Attorneys general of New York, California, New Jersey and Massachusetts are asking the Food and Drug Administration (FDA) to expand access to the abortion pill and remove some 'unnecessary' drug restrictions that have been in place for more than two decades. The joint petition, filed Thursday, comes days after FDA Commissioner Marty Makary committed to reviewing the abortion drug amid pressure from Department of Health and Human Services Secretary Robert F. Kennedy Jr. and some Republican lawmakers. The FDA first approved of the use of mifepristone and misoprostol for an abortion in 2000. Unlike surgical abortions, medication abortions do not need to take place in a clinical setting, and patients are able to take the pills at home. Most abortions in the U.S. are now medication abortions, according to data from the reproductive health and rights group Guttmacher Institute. In 2023, 63 percent of all abortions in the U.S. were medication abortions. The safety of mifepristone has come under increased scrutiny by some Republican lawmakers, citing a flawed study claiming the rate of adverse health events that occur among patients is far higher than previously reported. More than 100 scientific studies have been conducted looking at the safety and efficacy of mifepristone and misoprostol; all of them have found that the drugs are a safe way to terminate a pregnancy. 'Given Mifepristone's 25-year safety record, there is simply no scientific or medical reason to subject it to such extraordinary restrictions,' New York Attorney General Letitia James said. 'The FDA must follow the science and lift these unnecessary barriers that put patients at risk and push providers out of care.' Mifepristone's use is subject to a Risk Evaluation and Mitigation Strategy (REMS) program under the FDA. The attorneys general argue three requirements under the REMS program for the drug should be removed since they pose a burden to patients and health care systems. The first is related to prescriber certification. As part of the REMS program, health care providers who prescribe mifepristone are required to add their names to national and abortion provider lists, which the attorneys general say raise 'serious safety and legal concerns.' The second has to do with patient agreement forms. All patients who want mifepristone — even those using the drug to treat a miscarriage — are required to sign a document stating they are using the drug to end a pregnancy. The third requirement mentioned in the petition is connected to pharmacy certification. As part of mifepristone's REMS program, pharmacies that carry the drug are subject to tracking, shipping and reporting requirements, which the attorneys general argue may 'dissuade' some from carrying the drug. The FDA has yet to reply to a request for comment from The Hill about the petition.
